60 Degrees Pharmaceuticals (SXTP) Q2 2024 Earnings
SXTP·Reported August 14, 2024·Before market open
60 Degrees Pharmaceuticals reported Q2 2024 revenue of $125.0K, beat analyst consensus of $100.0K by $25.0K. Diluted EPS came in at $-21.15, missed the $-19.80 consensus by $1.35.
Revenue
$125.0Kbeat by $25.0K
Consensus: $100.0KDiluted EPS
$-21.15missed by $1.35
Consensus: $-19.80
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about 60 Degrees Pharmaceuticals's Q2 2024 earnings report.
60 Degrees Pharmaceuticals (SXTP) reported Q2 2024 earnings on August 14, 2024 before market open.
60 Degrees Pharmaceuticals reported revenue of $125.0K and diluted EPS of $-21.15 for Q2 2024.
Revenue beat the consensus estimate of $100.0K by $25.0K. EPS missed the consensus estimate of $-19.80 by $1.35.
You can read the 10-Q periodic report (0001213900-24-068673) directly on SEC EDGAR. The filing index links above go to sec.gov.